Triplet therapy effective for metastatic prostate cancer subset regardless of disease volume
Treatment intensification with darolutamide plus androgen deprivation therapy and docetaxel improved OS among men with metastatic hormone-sensitive prostate cancer regardless of disease volume or risk, according to study results.
The benefits of early treatment intensification appeared consistent among men with high-volume or low-volume disease, as well as those with high-risk or low-risk disease, a secondary analysis of the randomized phase 3 ARASENS trial presented at ASCO Genitourinary Cancers Symposium and published in Journal of Clinical Oncology showed.
Healio spoke with Maha H. A. Hussain, MD, FACP, FASCO — deputy director and leader of the genitourinary oncology program at Robert H. Lurie Comprehensive Cancer Center at Northwestern University Feinberg School of Medicine, as well as a Healio | HemOnc Today Editorial Board member — about the findings and their implications.
Collapse